Valuation: StemCell Institute Inc.

Market Cap 780.44Cr 4.91Cr 4.21Cr 3.93Cr 3.6Cr 6.76Cr 469.71Cr 6.85Cr 46Cr 18Cr 235.95Cr 18Cr 18Cr P/E 2026
49.6x
P/E 2027 * 71.1x
Enterprise Value 780.44Cr 4.91Cr 4.21Cr 3.93Cr 3.6Cr 6.76Cr 469.71Cr 6.85Cr 46Cr 18Cr 235.95Cr 18Cr 18Cr EV / Sales 2026
2.74x
EV / Sales 2027 * 2.52x
Free-Float
22.67%
Yield 2026 *
-
Yield 2027 * -
1 week+2.38%
Current month+9.15%
1 month+6.02%
3 months+20.53%
6 months-10.51%
Current year-2.27%
1 week 757
Extreme 757
775
1 month 699
Extreme 699
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,025
3 years 627
Extreme 627
2,776
5 years 627
Extreme 627
3,365
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 01/06/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 53 01/09/2013
Director/Board Member 81 01/06/2015
Director/Board Member 66 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.38%-24.39%-69.02% 4.91Cr
-0.67%-4.26%+30.23%+38.67% 12TCr
+5.64%+6.06%+6.17%+56.17% 9.29TCr
+1.28%+4.26%+33.02%+83.90% 2.7TCr
-0.25%+4.12%-3.92%-8.54% 2.22TCr
+3.00%+4.80%+58.28%+291.97% 2.26TCr
+1.48%+1.75%-8.03%+14.24% 1.45TCr
-1.83%-2.19%-7.94%-8.92% 1.24TCr
-0.81%-3.47%+26.34%+70.60% 1.11TCr
+2.54%+4.26%-3.64%+38.16% 1.04TCr
Average +1.04%+1.77%+10.61%+50.72% 3.32TCr
Weighted average by Cap. +1.68%+1.13%+19.06%+59.52%

Financials

2026 2027 *
Net sales 287Cr 1.81Cr 1.55Cr 1.45Cr 1.32Cr 2.49Cr 172.73Cr 2.52Cr 17Cr 6.67Cr 87Cr 6.78Cr 6.63Cr 310Cr 1.95Cr 1.67Cr 1.56Cr 1.43Cr 2.68Cr 186.57Cr 2.72Cr 18Cr 7.2Cr 94Cr 7.32Cr 7.16Cr
Net income 18Cr 11.32L 10L 9L 8L 15.59L 11Cr 15.8L 1.07Cr 41.81L 5.44Cr 42.51L 41.59L 11Cr 7L 6L 6L 5L 10L 6.62Cr 10L 65.52L 25.55L 3.33Cr 25.98L 25.42L
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
21/26/21 JP¥775.00 0.00% 14,900
20/26/20 JP¥775.00 +0.65% 4,300
19/26/19 JP¥770.00 -0.39% 4,600
18/26/18 JP¥773.00 +0.65% 10,200
17/26/17 JP¥768.00 +1.45% 10,100

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock